BM-011 / WASp modulator portfolio
Leukemias, Lymphomas, Autoimmune diseases (e.g., arthritis, colitis)
PreclinicalActive
Key Facts
Indication
Leukemias, Lymphomas, Autoimmune diseases (e.g., arthritis, colitis)
Phase
Preclinical
Status
Active
Company
About Bimini Biotech
BIMINI Biotech is a private, preclinical-stage biotech company pioneering a novel approach to treating cancer and autoimmune disorders through modulation of the Wiskott-Aldrich Syndrome protein (WASp). The company has built a proprietary portfolio of small-molecule WASp modulators, including its lead candidate BM-011, licensed from the Institute of Oncology Research. With a seasoned leadership team and backing from public grants and investors like InnovationQuarter, BIMINI is advancing its lead programs toward first-in-human studies, targeting significant unmet needs in hematological cancers and autoimmunity.
View full company profile